BVS - Bioventus stock rises as FDA clears SonaStar Elite for use in tumor removal

• The U.S Food and Drug Administration (FDA) granted 510(k) clearance to Bioventus' ( NASDAQ: BVS ) neXus SonaStar Elite handpiece for resection of tumors.
• The company said the SonaStar Elite (SSE) handpiece is powered by the neXus Ultrasonic Surgical Aspirator System, an ultrasonic surgical platform. The neXus system combines all the features of soft and hard (including bone) tissue removal into a single integrated platform capable of operating at multiple frequencies, including the newly approved 36 kHz SSE handpiece.
• Bioventus added that while the neXus system can be used in many clinical applications including neurosurgery, SSE handpiece has been cleared for resection of tumors with varying consistencies ranging from soft to firm, including removal of malignant and benign brain and spinal tumors.
• BVS +6.67% to 9.28 premarket Aug. 3

For further details see: